Teva Pharmaceutical Industries Limited (TEV) — Cash Flow-to-Debt Ratio
Teva Pharmaceutical Industries Limited (TEV) has a Cash Flow-to-Debt Ratio of 0.00x as of March 2026, meaning its operating cash flow of €-40.00 Million could theoretically repay 0% of its total liabilities (€31.81 Billion) in one year. See TEV cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Teva Pharmaceutical Industries Limited Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Teva Pharmaceutical Industries Limited across 11 annual periods. Also explore TEV net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Teva Pharmaceutical Industries Limited (2015–2025)
Year-by-year debt coverage analysis for Teva Pharmaceutical Industries Limited. For market capitalisation and broader financial context, see TEV market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.05x | €1.65 Billion | €32.83 Billion | ▲ +35.3% |
| 2024 | 0.04x | €1.25 Billion | €33.61 Billion | ▲ +13.4% |
| 2023 | 0.03x | €1.16 Billion | €35.35 Billion | ▼ -27.3% |
| 2022 | 0.05x | €1.59 Billion | €35.31 Billion | ▲ +105.5% |
| 2021 | 0.02x | €798.00 Million | €36.42 Billion | ▼ -28.7% |
| 2020 | 0.03x | €1.22 Billion | €39.58 Billion | ▲ +74.2% |
| 2019 | 0.02x | €748.00 Million | €42.41 Billion | ▼ -67.6% |
| 2018 | 0.05x | €2.45 Billion | €44.89 Billion | ▲ +27.0% |
| 2017 | 0.04x | €2.23 Billion | €51.87 Billion | ▼ -36.2% |
| 2016 | 0.07x | €3.89 Billion | €57.90 Billion | ▼ -70.5% |
| 2015 | 0.23x | €5.54 Billion | €24.31 Billion | — |